|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
09.06.26 - 10:18
|
Sanofi Buy (DPA-AFX)
|
|
|
FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Sanofi mit einem Kursziel von 100 Euro auf "Buy" belassen. Dies schrieb Emmanuel Papadakis in seinem am Dienstag vorliegenden Kommentar zu den wöchentlichen Verschreibungszahlen./rob/agVeröffentlichung ......
|
|
|
09.06.26 - 07:06
|
Cursor Announces EMEA Office and Team Expansion to Meet Regional Demand (Business Wire)
|
|
|
London headquarters will open this summer and grow to approximately 200 employees by year-end as EMEA becomes Cursor's fastest-growing regionLONDON--(BUSINESS WIRE)--Cursor, the leading multi-model AI coding platform, today announced the establishment of dedicated teams to serve the EMEA region. The expansion responds to regional momentum, with EMEA revenue tripling quarter over quarter this year.
The Cursor EMEA team will support a rapidly expanding customer base that includes British Airways, BP, Deliveroo, Nokia, Sanofi and many other leading enterprises across the region. Cursor expects to grow its EMEA headcount to approximately 200 employees by the end of the year, hiring across go-to-market, engineering, customer success and operations.
“We're incredibly excited to officially launch Cursor across EMEA and deepen our commitment to customers and partners throughout Europe. As the leading AI coding company, our goal is simple: be closer to the teams building the future and help enterprises acceler...
|
|
|
|
|
08.06.26 - 12:00
|
Sanofi and Owkin partner to develop next-generation biopharma AI agents (PBR)
|
|
|
The partnership includes a five-year licence for Owkin's K Pro, an AI platform designed to augment drug discovery and development. Since 2021, Sanofi and Owkin have maintained a
The post Sanofi and Owkin partner to develop next-generation biopharma AI agents appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
07.06.26 - 13:12
|
Nach brutalem Tech-Abverkauf: Jetzt auf diesen europäischen Dividenden-Champion setzen? (Ariva)
|
|
|
Der französische Pharmakonzern Sanofi bietet nach einer hartnäckigen Korrektur eine attraktive Bewertung und eine überdurchschnittlich hohe Dividendenrendite. Crash bei Technologie- und Wachstumswerten Der brutale Abverkauf bei Technologie- und Wachstumswerten am vergangenen Freitag hat schonungslos offengelegt, wie einseitig die vermeintlich starke Aktienmarktrallye in den vergangenen zwei Monaten war. Überraschend starke Arbeitsmarktdaten haben ......
|
|
|
|
|
|
|
04.06.26 - 09:06
|
Veeva Summit Previews Falcon and the Path to Agentic Biopharma (PR Newswire)
|
|
|
More than 2,000 gathered to see the future of industry AI AOP Health, Boehringer Ingelheim, GSK, Haleon, MSD, Novo Nordisk, Roche, Sanofi, and Sobi among leaders sharing strategies to streamline and connect operations BARCELONA, Spain, June 4, 2026 /PRNewswire/ -- At the recent Veeva R&D......
|
|
|
04.06.26 - 08:03
|
Sanofi Buy (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Sanofi mit einem Kursziel von 100 Euro auf "Buy" belassen. Bei den Franzosen gebe es trotz des Führungswechsels keinen Stillstand, schrieb Michael Leuchten am Mittwochabend ......
|
|
|
02.06.26 - 15:06
|
Wayleadr Announces Majority Growth Investment to Accelerate Global Expansion (Business Wire)
|
|
|
SAN FRANCISCO--(BUSINESS WIRE)--Wayleadr, the category-defining Arrival Platform transforming how people and vehicles access workplaces and parking, today announced a majority growth investment to accelerate the company's next phase of global expansion.
Founded in 2016 by entrepreneur Garret Flower, Wayleadr pioneered the Arrival Platform category, helping many of the world's leading enterprises modernize parking, workplace access, and visitor management across global portfolios. Today, the platform powers millions of seamless arrivals annually for organizations including OpenAI, Google, Uber, Novartis, Sanofi, Riot Games, and other leading global enterprises.
Under Flower's leadership as Founder & CEO, Wayleadr expanded internationally across 10+ countries, with a strong focus on the US market, becoming one of the most recognized technology platforms in workplace operations.
“This is an important milestone for Wayleadr and a reflection of what the team has built over the past several years,” said ...
|
|
|
|
|
29.05.26 - 12:00
|
FDA grants priority review for Sanofi′s venglustat NDA (PBR)
|
|
|
If approved, venglustat would be the first treatment in the US to address the neurological symptoms of GD3, which currently have no targeted therapies. The decision is anticipated
The post FDA grants priority review for Sanofi's venglustat NDA appeared first on Pharmaceutical Business review....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
